Ampio Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael A. Martino
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 373 Inverness Parkway Englewood CO United States of America 80112
- IPO Date
- Mar 31, 2010
- CIK
- 0001411906
- Website
- ampiopharma.com
- Similar Companies
- Business
- Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), headquartered in Englewood, Colorado and founded in 2009, operates as a development-stage biopharmaceutical company focused on discovering and developing novel therapies for inflammatory conditions, including osteoarthritis of the knee (OAK), metabolic diseases, eye disorders, kidney disease, and central nervous system (CNS) ailments; its core pipeline historically features immunology-based products such as Ampion, a biologic for OAK backed by patents extending through 2037, alongside small-molecule formulations like OA-201 and OA-20X aimed at pain reduction and cartilage protection in preclinical rodent models, with additional exploration of new molecular entities (NMEs) and repurposed approved drugs for sexual dysfunction and inflammation. The company targets patients with limited treatment options through clinical and manufacturing capabilities, primarily serving the U.S. market while pursuing global intellectual property protection and FDA approvals under pathways like the Biologics Price Competition and Innovation Act. In recent developments, Ampio Pharmaceuticals selected Ascendia Pharmaceuticals, Inc. as its contract development and manufacturing organization (CDMO) partner in October 2023 to support formulation, process optimization, and cGMP manufacturing for the OA-201 program's Phase 1-3 clinical trials following promising preclinical data; it engaged Bruder Consulting & Venture Group for preclinical and clinical strategy in osteoarthritis; announced operational streamlining with staff reductions and facility subleases to save approximately $4.6 million annually; implemented a reverse stock split and Series D Preferred Stock dividend; and, most significantly, stockholder-approved a Plan of Dissolution on August 15, 2024, resulting in formal dissolution on August 16, 2024, voluntary delisting from NYSE American, SEC deregistration, and ongoing settlement of legal obligations including a January 2025 derivative stipulation, with potential cash distributions to stockholders pending Delaware Chancery Court approval.
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC)
Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)
Ampio Pharmaceuticals (NYSE:AMPE) and Graybug Vision (NASDAQ:GRAY) Financial Contrast
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Provides Update on Results from Pre-IND Enabling Studies
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
Ampio Pharmaceuticals Announces Reverse Stock Split
3 Biotech Stocks to Buy With Explosive Upside Potential
ROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMPE
Which Strategies Are You Using With Penny Stocks in September?
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMPE
Why These 3 Penny Stocks Are Climbing in Late April
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
New Strong Sell Stocks for April 7th
New Strong Sell Stocks for April 1st
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript